PT Kalbe Farma Unsponsored Indonesia ADR (PTKFY) Stock Price & News

PT Kalbe Farma Tbk, or simply known as Kalbe, is an Indonesian pharmaceutical, healthcare and nutrition company established in 1966. The company has expanded by strategic acquisitions of pharmaceutical companies, becoming an integrated consumer health and nutrition enterprise. The Kalbe Group has brands in the prescription drugs, OTC drugs, energy drink and nutrition products, with a distribution arm that reaches over one million outlets. Notably, the company produces misoprostol, a drug which is used to treat stomach ulcers but is also widely used in Indonesia as an illegal abortifacient. Company brands in healthcare and pharmaceutical segments include Promag, Mixagrip, Woods, Komix, Diabetasol, Prenagen, Extra Joss and Fitbar. Kalbe is the largest publicly listed pharmaceutical company in Southeast Asia with around US$5 billion in market capitalization and revenues of over Rp 15 trillion. The name "Kalbe" is a syllabic abbreviation of its founder's name: Khouw Lip Boen. Wikipedia

About PT Kalbe Farma Unsponsored Indonesia ADR

CEO-

Employees12,8 k

Founded10 Sep. 1966

Headquarters-

SectorPharmaceutical industry

Websitekalbe.co.id

All values in IDR	Sep. 2025	Des. 2025	Mrt. 2026	Jun. 2026
Revenue	8,91 bn	9,34 bn	9,68 bn	9,80 bn
Cost of goods sold	5,46 bn	5,92 bn	6,02 bn	6,25 bn
Cost of revenue	5,46 bn	5,92 bn	6,02 bn	6,25 bn
Research and development expenses	98,31 mjd	160,88 mjd	113,14 mjd	122,60 mjd
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	2,51 bn	1,95 bn	2,23 bn	2,27 bn
Operating expense	2,60 bn	2,14 bn	2,33 bn	2,39 bn
Total operating expenses	8,06 bn	8,05 bn	8,36 bn	8,64 bn
Operating income	851,77 mjd	1,28 bn	1,32 bn	1,16 bn
Other non operating income	-3,78 mjd	-4,17 mjd	-3,63 mjd	-3,74 mjd
EBT including unusual items	877,87 mjd	1,30 bn	1,36 bn	1,19 bn
EBT excluding unusual items	888,55 mjd	1,30 bn	1,36 bn	1,18 bn
Income tax expense	211,19 mjd	252,81 mjd	303,84 mjd	271,57 mjd
Effective tax rate	24,06%	19,41%	22,40%	22,80%
Other operating expenses	-7,23 mjd	31,35 mjd	-10,02 mjd	2,13 mjd
Net income	656,41 mjd	1,03 bn	1,03 bn	890,54 mjd
Net profit margin	7,37%	11,07%	10,63%	9,09%
Earnings per share	14,44	22,72	22,74	19,68
Interest and investment income	41,31 mjd	40,43 mjd	32,07 mjd	43,61 mjd
Interest expense	-9,69 mjd	-5,77 mjd	-4,61 mjd	-6,78 mjd
Net interest expenses	31,62 mjd	34,66 mjd	27,46 mjd	36,83 mjd
Depreciation and amortization charges	-	-	-	-
EBITDA	1,05 bn	1,45 bn	1,51 bn	1,20 bn
Gain or loss from assets sale	-	-	-	-

Finance

Ask anything